In fact, a phase 2 clinical trial demonstrated that the small molecule baricitinib, a selective JAK1 and JAK2 inhibitor, effectively lowered albuminuria in patients with type 2 diabetes and diabetic kidney disease (Tuttle et al., 2018). This evidence concerns the gene JAK1 and diabetic kidney disease.